Four Approved ALK Lung Cancer Pills Compared in Patient Records
Original title: Comparative Effectiveness of First-Line Tyrosine Kinase Inhibitors in ALK-Positive Metastatic Non-Small Cell Lung Cancer by Presence of Brain Metastases.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
All four pills are approved, and doctors can prescribe them today.
The short version
Doctors looked back at records of 1623 people to compare four approved pills.
What was studied. Researchers checked insurance records of 1623 people with ALK positive lung cancer that had spread. Each one took one of four approved pills first: alectinib, brigatinib, crizotinib, or lorlatinib. The team also looked at people whose cancer spread to the brain.
What they found. The full dose was reached by 97% of people on alectinib, 89% on brigatinib, and 70% on lorlatinib. By 12 months, 79%, 78%, and 65% were still on the full dose. Brigatinib did not look better or worse than alectinib or lorlatinib for how long people lived.
What this means, and what it doesn't
What it could mean: All four pills are already in use today. People on alectinib or brigatinib stayed on the full dose more often. Your doctor can talk with you about which pill fits your case.
What it doesn't mean: This does not mean one pill is proven better than another. The study looked back at old insurance records. It was not a planned trial that tested the pills side by side. Only 58 people took brigatinib and 81 took lorlatinib. That is too few to be sure. These results are not a promise of a cure.
Source: PubMed, August 27, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.